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Abstract 
Objective: The main aim of study was to investigate the prevalence of risk factors and osteoporosis in chronic 
obstructive pulmonary disease patients. 
Methods:  This prospective cross sectional study was done in pulmonology department Nishtar Hospital Multan. 
Total 369 patients of chronic obstructive pulmonary disease, diagnosed according to Global Initiative for 
Chronic Obstructive Lung Diseases (GOLD) criteria were enrolled by non-probability consecutive sampling. 
The study was conducted from January 2016 to November 2016. Ethical approval was taken from committee of 
the hospital. Written permission was signed by each patient included in study. Quantitative variables like age, 
body mass index, FEV1, pack years smoking and vitamin D were statistically measured in mean and standard 
deviation. Qualitative variables like gender and area of living were statistically analyzed in percentage and 
frequency. ANNOVA was applied to test the significance. P value <0.05 was taken as significant. 
Results:  Overall, 100% (n=369) patients were included, in this study; divided into two groups i.e. non-
osteoporosis 60% (n=220) and osteoporosis 40% (n=149). The mean age, BMI and smoking pack-years of the 
non-osteoporosis patients was 67.99±4.61 years, 23.92±1.95 kg/m2 and 41.62±10.20 respectively. There were 
94.1% (n=207) males and 5.9% (n=13) females. While, the mean age, BMI and smoking pack-years of the 
osteoporosis patients was 71.44±3.90 years, 21.91±3.26 kg/m2 and 49.05±3.00 respectively. There were 97.3% 
(n=145) males and 2.7% (n=4) females. Education status of the non-osteoporosis patients observed as 36.4% 
(n=80) illiterate and 63.6% (n=140) elementary or above, while there were 38.3% (n=57) osteoporosis patients 
illiterate and 61.7% (n=92) were elementary or above. Significant differences were found between age 
(p=0.000), BMI (p=0.000), smoking pack years (p=0.000), BMD T-score (p=0.000), Systolic BP (p=0.000), 
Diastolic BP (p=0.000), FVC, liters (p=0.000), FVC, predicted%, (p=0.000), FEV1, liters (p=0.000), FEV1, 
predicted% (p=0.000) and FEV1/FVC (p=0.000), in groups. Association was found between HTN (p=0.000) and 
GOLD (p=0.001) in groups. 
Conclusion: Study concluded that osteoporosis is hidden and common comorbidity in chronic obstructive 
pulmonary disease patients. Its prevalence was high among the patients. ------ were independent risk factors in 
developing osteoporosis in chronic obstructive pulmonary disease patients. Pulmonologists should consider and 
properly investigate osteoporosis in chronic obstructive pulmonary disease patients. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is very common respiratory problem. It is a chronic 
inflammatory disease of lung {1}. Systemic chronic inflammation is caused by TNF-alpha, IL-6, CRP and IL-8 
{2}. It greatly affects the quality of life {3}. Chronic obstructive pulmonary disease is characterized by persistent 
and irreversible air flow limitation {4}. Chronic obstructive pulmonary disease is treatable and progressive 
disease. Chronic obstructive disease occurs in adults and older age patients. Patients of chronic obstructive 
disease clinically present with symptoms of cough, chest pain, dyspnea and sputum mostly. It is cause of great 
burden on health care system. Chronic obstructive disease is one of the leading cause of mortality. It is expected 
to be the third most common cause of mortality in 2020 {5}. Many complications occur in chronic obstructive 
pulmonary disease patients like anemia, muscle wasting, cachexia and weight loss. Most cases of chronic 
obstructive pulmonary disease occur due to smoking {6}. Other factors such as bio mass fuel exposure {7}, 
environmental pollution, toxic agents on work place can cause chronic obstructive pulmonary disease. 
Inflammation to these hazardous agents in airways result in bronchospasm and mucous glands hyperplasia. 
Chronic obstructive pulmonary disease patients usually have many comorbidities like diabetes, hypertension and 
cardiovascular disease. Erectile dysfunction is also common problem in chronic obstructive pulmonary disease 
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patients {8}. Acute exacerbation of chronic obstructive pulmonary disease is crucial event in the course of 
disease. It is main reason of hospitalization in chronic obstructive pulmonary disease patients. It is estimated that 
50-70% cost associated with chronic obstructive pulmonary disease is due to its exacerbation.  
Osteoporosis is bone disorder which is caused by change in micro architectural of the skeleton due to low bone 
mineral density (BMD) {9}. Bone strength and quality mainly depends on the three dimensional micro 
architectural of bone and also properties of material constituents. Type 1 collagen and hydroxyapatite crystals 
are the main constituents of bone {10}. Osteoporosis increase the chances of fracture by compromising the bone 
strength. There is no clinical tool to evaluate the quality of bone. However, bone mineral density is measured by 
dual-energy X-ray absorptiometry (DXA). According to WHO criteria osteoporosis is diagnosed when bone 
mineral density is 2.5 standard deviation or more to young adult mean. Bone mineral density reflects nearly 70% 
strength of bone. 
It has been investigated that there is a strong association of osteoporosis in COPD patients. The development of 
osteoporosis in chronic obstructive pulmonary disease patients is caused by many risk factors. Age, smoking, 
low body mass index, use of steroid, low levels of vitamin D, decrease physical activity and chronic 
inflammation are the common factors that result in osteoporosis in chronic obstructive pulmonary disease 
patients. Osteoporosis has its complications in chronic obstructive pulmonary disease patients. It increases the 
chances of osteoporotic fractures and affects the quality of life {11}. 
Rationale of the study was that osteoporosis is common and hidden comorbidity in chronic obstructive 
pulmonary disease patients. It is extremely under investigated and undertreated condition in chronic obstructive 
pulmonary disease. Currently, very limited research had been conducted on prevalence and risk factors of 
osteoporosis in chronic obstructive pulmonary disease in Pakistan. So this study will help to establish the facts 
and also provide base for further investigation. Study done by Chun-Wei lin et al. in Taiwan was taken as 
reference study {12}. 
 
Materials and methods 
This prospective cross sectional study was done in pulmonology department Nishtar Hospital Multan. Total 369 
patients of chronic obstructive pulmonary disease, diagnosed according to Global Initiative for Chronic 
Obstructive Lung Diseases (GOLD) criteria were enrolled by non-probability consecutive sampling. The study 
was conducted from January 2016 to November 2016. Ethical approval was taken from committee of the 
hospital. Written permission was signed by each patient included in study. All patients having clinically stable 
chronic obstructive pulmonary disease disease and can perform mild physical activity were included in study. 
Exclusion criteria of study were: 1) patients who were using systemic corticosteroids, 2) patients having history 
of any malignancy, 3) any history of acute exacerbation of chronic obstructive pulmonary disease in last one 
year, 4) patients having history of other systemic diseases like endocrine, renal, gastrointestinal, cardiovascular 
and rheumatology which can effect bone mineralization and patients having other than chronic obstructive 
pulmonary disease respiratory disorder were excluded from the study. Sample size was collected from a 
reference study done by Chun Wei Lin et al. for which confidence interval was taken as 95%, study strength 80, 
40% of chronic obstructive pulmonary disease patients having osteoporosis {12}. 
All patients were recruited from outpatient department. A detailed history of disease, smoking habits, history of 
pain and physical activity were taken. Complete physical examination was done in every patient to assess the 
severity of disease, its complications and any clue of other systemic disorder. Personal information of each 
patient like age, gender, body mass index, area of living and smoking status was recorded by filling the 
Performa. On the investigation day pulmonary function tests, bone mineral density and fasting blood glucose 
were recorded. 
Spirometry was done to check the pulmonary functions. It was done by same technician in each patient and in 
sitting position. Three technically correct values of FEV1, FVC and FEC1/FVC were recorded and highest of 
three value was taken in study. 
Bone mineral density was checked by using dual energy X ray absorptiometry (DEXA). Left hip joint, anterior 
posterior lumbar spine (L1 to L4) and total bone mineral density were measured individually in absolute values 
in grams of minerals per unit area scanned (g/cm) and relative T-scores. According to WHO criteria osteoporosis 
is diagnosed when bone mineral density is 2.5 standard deviation or more to young adult mean 
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In all patient’s venous sample was drawn between 6 a.m. to 9 a.m. Complete blood analysis and fasting blood 
sugar levels were measured  
Quantitative variables like age, body mass index, FEV1, pack years smoking and vitamin D were statistically 
measured in mean and standard deviation. Qualitative variables like gender and area of living were statistically 
analyzed in percentage and frequency. ANNOVA was applied to check the significance. P value <0.05 was taken 
as significant. 
 
Results 
Overall, 100% (n=369) patients were included, in this study; divided into two groups i.e. non-osteoporosis 60% 
(n=220) and osteoporosis 40% (n=149). The mean age, BMI and smoking pack-years of the non-osteoporosis 
patients was 67.99±4.61 years, 23.92±1.95 kg/m2 and 41.62±10.20 respectively. There were 94.1% (n=207) 
males and 5.9% (n=13) females. While, the mean age, BMI and smoking pack-years of the osteoporosis patients 
was 71.44±3.90 years, 21.91±3.26 kg/m2 and 49.05±3.00 respectively. There were 97.3% (n=145) males and 
2.7% (n=4) females. Education status of the non-osteoporosis patients observed as 36.4% (n=80) illiterate and 
63.6% (n=140) elementary or above, while there were 38.3% (n=57) osteoporosis patients illiterate and 61.7% 
(n=92) were elementary or above (Table. 1). 
 The mean BMD T-score, Systolic BP, Diastolic BP, FVC liters, FVC predicted %, FEV1 liters, FEV1 
predicted % and FEV1/FVC of the non-osteoporosis patients was -1.54±0.49, 140.41±12.38 mm/Hg, 84.85±5.28 
mm/Hg, 2.46±0.57 liters, 64.87±10.82 %, 1.68±0.22 liters, 60.13±2.68 % and 62.95±5.74 respectively.  While, 
the mean BMD T-score, Systolic BP, Diastolic BP, FVC liters, FVC predicted %, FEV1 liters, FEV1 predicted % 
and FEV1/FVC of the osteoporosis patients was -2.79±0.86, 135.99±8.19 mm/Hg, 78.08±6.57 mm/Hg, 
1.81±0.54 liters, 56.08±2.34 %, 1.11±0.28 liters, 49.21±2.94% and 54.28±5.19 respectively. DM was noted as 
13.2% (n=29) and 9.4% (n=14) for non-osteoporosis and osteoporosis groups respectively. HTN was noted as 
62.3% (n=137) and 43% (n=64) for non-osteoporosis and osteoporosis groups respectively (Table. 2). The 
classification of Global initiative for chronic obstructive lung disease GOLD groups (A-D) was shown in table 3. 
 Significant differences were found between age (p=0.000), BMI (p=0.000), smoking pack years 
(p=0.000), BMD T-score (p=0.000), Systolic BP (p=0.000), Diastolic BP (p=0.000), FVC, liters (p=0.000), 
FVC, predicted%, (p=0.000), FEV1, liters (p=0.000), FEV1, predicted% (p=0.000) and FEV1/FVC (p=0.000), in 
groups. Association was found between HTN (p=0.000) and GOLD (p=0.001) in groups. So, HTN and GOLD 
were the effect modifiers for osteoporosis (Table. 1-2). 
Table. 1 
Demographic Variables 
Variable 
Non-osteoporosis 
n=(220) 
Osteoporosis 
n=(149) Test of Sig. 
Age 
67.99±4.61 years 71.44±3.90 
years 
t=-7.48 
p=0.000 
BMI* 
23.92±1.95 kg/m2 21.91±3.26 
kg/m2 
t=7.36 
p=0.000 
Smoking 
Pack years 
41.62±10.20 49.05±3.00 t=-8.63 
p=0.000 
Gender 
M=94.1%, 
F=5.9% 
M=97.3%, 
F=2.7% 
χ2=2.102 
p=0.147 
Education 
Status 
Illiterate=36.4%, 
literate=63.6% 
Illiterate=38.3%, 
literate=61.7% 
χ2=0.136 
p=0.712 
*BMI; Body Mass Index. 
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Table. 2 
Variable 
Non-osteoporosis 
n=(220) 
Osteoporosis 
n=(149) Test of Sig. 
BMD T-
score 
-1.54±0.49 -2.79±0.86 t=17.69 
p=0.000 
Systolic BP 
140.41±12.38 135.99±8.19 t=3.82 
p=0.000 
Diastolic 
BP 
84.85±5.28 78.08±6.57 t=10.92 
p=0.000 
FVC, liters 
2.46±0.57 1.81±0.54 t=10.93 
p=0.000 
FVC, 
predicted% 
64.87±10.82 56.08±2.34 t=9.76 
p=0.000 
FEV1, liters 
1.68±0.22 1.11±0.28 t=21.47 
p=0.000 
FEV1, 
predicted% 
60.13±2.68 49.21±2.94 t=36.82 
p=0.000 
FEV1/FVC 
62.95±5.74 54.28±5.19 t=14.78 
p=0.000 
DM* 
Yes=13.2% Yes=9.4% χ2=1.23 
p=0.266 
HTN* 
Yes=62.3% Yes=43% χ2=13.37 
p=0.000 
* BP, blood pressure; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; 
DM, diabetes mellitus; HTN, hypertension 
 
Table. 3 
GOLD* 
Groups 
Test of Sig. Non-osteoporosis 
 
Osteoporosis 
 
Group A (n=26), 11.8% (n=11), 7.4% χ2=15.85 
p=0.001 Group B (n=120), 54.5% (n=57), 38.3% 
Group C (n=60), 27.3% (n=64), 43.0% 
Group D (n=14), 6.4% (n=17), 11.4% 
Total (n=100), 100% (n=100), 100% 
*GOLD, Global Initiative for Chronic Obstructive Lung Disease 
 
Discussion 
Results of this study showed two things. One that osteoporosis is common among chronic obstructive pulmonary 
disease patients. Second risk factors which were significantly associated with development of osteoporosis in 
COPD. Study showed that 40% patients of COPD had osteoporosis. Study also concluded that FEV1, body mass 
index, percentage of diabetes and hypertension were lower in COPD patients who had osteoporosis than patients 
who had no osteoporosis. Average smoking pack years were higher in osteoporotic group than non-osteoporotic 
group. Vary similar results were demonstrated by a study done by Chun Wei Lin et al. {12}. In this study forty 
percent COPD patients had osteoporosis. Body mass index and FEV1 were significantly associated with 
development of osteoporosis.  
COPD is systemic chronic inflammatory disease. This inflammation in COPD, as demonstrated by oxidative 
stress, raised red cell distribution width, elevated levels of CRP and pro inflammatory mediators, results in 
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protein catabolism {13}. Study done by Reiko Watanabe et al. in Japan showed that there is significant 
prevalence of osteoporosis in male COPD patients {14}. Study done by N.R.Jørgensen et al. showed that 68% 
COPD patients had osteoporosis and osteopenia {15}. A three years follow up study done by LidwienGraat-
Verboom et al. reported an increase in prevalence of osteoporosis from 47% to 61% {16}. 
 
Smoking also risk factor for developing osteoporosis {17}. Smoking pack years were higher in osteoporotic 
group of COPD patients. Smoking cause absorption of bone by lowering pH of bone salts {18}. Smoking also 
induces systemic inflammatory response in the body. Initial point of this inflammation starts from lung which 
results in production of systemic inflammatory mediators which results in absorption of bone. Study done by K 
A Hollenbach et al. concluded that smoking is significantly associated with decrease bone mineral density of hip 
bone and increase chances of fractures in hip bone {19}. Result of study done by Chun Hay Ko et al. showed 
that even passive smoking can cause osteopenia. It effects bone cell differentiation and bone remodeling process 
{20}. Study done by Ill PO et al. showed that smoking is modest risk factor for development of osteoporosis 
{21}. 
 
Body mass index was lower in osteoporotic group of COPD patients. Result of the study done by Biplob 
Chowdhury et al.  showed that low body mass index predicts osteoporosis {22}. Study done by Kofi Asomaning 
et al. showed that women with lower body mass index are at increased risk of developing osteoporosis {23}. One 
study done by Terence Ong et al. showed that higher body mass index as in obesity is not protective against 
fractures {24}.  
Result of this study showed that value of FEV1 was lower in COPD patients who develop osteoporosis. A study 
conducted in Japan in male COPD patients reported that low FEV1 is independent risk factor of developing 
osteoporosis {14}. Another study conducted by Shahid Sheikh et al. in cystic fibrosis patients showed that 
osteoporosis is common in patients having low FEV1 {25}.  
 
Higher percentage of diabetic patients were found in osteoporotic group. Study done by Dana Hyassat et al. 
reported that women with type 2 diabetes mellitus had lower risk of developing osteoporosis {25}.  
So results of this study had shown that osteoporosis is hidden, under considered and very common comorbidity 
in COPD patients. Many risk factors are involved in developing osteoporosis in COPD patients.  
Limitation of the study was that sample size was relatively small and it covered a short geographical area. Study 
design was also its limitation. 
Conclusion 
Study concluded that osteoporosis is hidden and common comorbidity in COPD patients. Its prevalence was 
high among the patients. Significant number of COPD patients had osteoporosis. Pulmonologists should 
consider and properly investigate osteoporosis in COPD patients. 
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